Mouillaux, Julie
Allam, Camille
Gossez, Morgane
Uberti, Thomas
Delwarde, Benjamin
Hayman, Jack
Rimmelé, Thomas
Textoris, Julien
Monneret, Guillaume
Peronnet, Estelle
Venet, Fabienne http://orcid.org/0000-0003-0462-4235
Funding for this research was provided by:
Hospices Civils de Lyon
bioMerieux
Article History
Received: 6 June 2018
Accepted: 28 December 2018
First Online: 17 April 2019
Ethics approval and consent to participate
: This project was approved by our Institutional Review Board for Ethics (“Comité de Protection des Personnes Sud-Est II”), which waived the need for informed consent, as the study was observational and performed on residual blood, after the completion of routine follow-up (#IRB 11236). This study is registered at the French Ministry of Research and Teaching (#DC-2008-509), at the Commission Nationale de l’Informatique et des Libertés, and on ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT02803346). Non-opposition to inclusion in the study was registered for each patient.
: Not applicable.
: FV, GM, EP, and JT are co-inventors in three patent families covering IL-7 receptor biomarkers. This does not alter the authors’ adherence to all the <i>Critical Care</i> policies on sharing data and materials. JM, JT, GM, EP, and FV work in a joint research unit, co-funded by the Hospices Civils de Lyon, bioMérieux, and Lyon 1 University.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.